X

Trial Profile

Phase II Open 24 Weeks Study to Evaluate Effect and Safety of Tocilizumab as the First Line Therapy in Subjects With Polymyalgia Rheumatica (PMR)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Corticosteroid
Indications Polymyalgia rheumatica
Focus Therapeutic Use
Acronyms TENOR

Most Recent Events

15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
15 Mar 2019 Results of post-hoc analysis published in The Journal of Rheumatology.
20 Apr 2017 Results of correction of abnormal B-cell subset distribution (n=18) published in the Rheumatology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com